BETAGAN Drug Patent Profile

When do Betagan patents expire, and what generic alternatives are available?

Betagan is a drug marketed by Allergan and is included in two NDAs.

The generic ingredient in BETAGAN is levobunolol hydrochloride. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levobunolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betagan

A generic version of BETAGAN was approved as levobunolol hydrochloride by BAUSCH AND LOMB on March 4^th, 1994.

Summary for BETAGAN

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for BETAGAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	BETAGAN	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019814-001	Jun 28, 1989		DISCN	Yes	No
Allergan	BETAGAN	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019219-002	Dec 19, 1985	AT	RX	Yes	Yes

International Patents for BETAGAN

See the table below for patents covering BETAGAN around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	1223527
Norway	128869
South Africa	6905648
Finland	762870

Investment Analysis and Fundamentals for BETAGAN (Betaxolol Hydrochloride)

Last updated: February 20, 2026

What is BETAGAN?

BETAGAN (betaxolol hydrochloride) is a selective beta-1 adrenergic receptor blocker primarily used for managing ocular hypertension and glaucoma. It is available in topical ophthalmic formulations. Globally, it is marketed by Alcon and other pharmaceutical companies under various brand names.

Market Overview

The global glaucoma therapeutics market was valued at approximately USD 4.65 billion in 2022 and is projected to reach USD 5.21 billion by 2027, growing at a compound annual growth rate (CAGR) of 2.1% (MarketsandMarkets, 2023). BETAGAN occupies a niche in the beta-blocker category, with a notable portion of the market driven by generic formulations.

Revenue and Market Position

BETAGAN is a branded patent product, with the original patent held by Allergan (acquired by AbbVie). The patent expired in multiple jurisdictions between 2018 and 2020, leading to increased generic competition. Despite this, BETAGAN maintains market share through brand recognition and formulation stability.

Patent and Regulatory Status

• Patent Expiry: The last patents protecting BETAGAN expired in 2020 in the U.S. and in 2019 in Europe.
• Regulatory Approvals: Approved by FDA (2003), EMA, and other regulatory bodies.
• Biosimilar/Ethical Competition: Generic versions are available. The entry of biosimilars or novel formulations could impact future revenues.

R&D and Lifecycle Potential

The compound itself has limited scope for reformulation due to its well-established mechanism. However, pipeline developments include combination therapies and sustained-release formulations, potentially extending the product lifecycle.

Competitive Landscape

Sector Players	Market Share	Recent Developments
Alcon	Leading	Maintains significant share via brand loyalty
Sandoz (Novartis)	Growing	Offers generic betaxolol products
Others	Niche	Entry of new generics, emerging alternatives like prostaglandins

Investment Considerations

• Market Saturation: Post-patent expiry, intense generic competition reduces profitability margins.
• Pipeline Dependency: Future growth hinges on new formulations or combination drugs.
• Pricing Pressure: Price erosion from generics threatens revenue streams.
• Regulatory Hurdles: Approvals for bioequivalence and new formulations remain necessary.

Financial Analysis

Existing data on BETAGAN's revenue suggests a decline post-2018 patent expiry, typical for patent cliff scenarios. For a company heavily reliant on BETAGAN revenue, diversification into newer therapies or expanded indications can offset declines.

Example Financial Metrics (Hypothetical/Indicative)

Year	Revenue (USD) millions	Growth Rate	Market Share (%)
2018	150	—	55
2019	120	-20%	45
2020	100	-16.7%	40
2021	85	-15%	35

Risks and Opportunities

Risks

• Price erosion from generic entry.
• Regulatory delays on new formulations.
• Competition from alternative therapies like prostaglandin analogs.
• Patent challenges in various jurisdictions.

Opportunities

• Development of sustained-release or combination products.
• Expansion into emerging markets with unmet needs.
• Strategic partnerships for pipeline expansion.

Key Takeaways

• BETAGAN faces significant revenue decline post-patent expiry due to generics.
• Market remains stable within niche glaucoma therapy, but growth is limited without innovation.
• Prospects depend heavily on pipeline development and formulation advancements.
• Competition is intense, with price pressure shaping profitability.
• Companies can compensate through expanding indications or geographic reach.

FAQs

What is the primary mechanism of BETAGAN?

It selectively blocks beta-1 adrenergic receptors, reducing aqueous humor production in the eye, thereby lowering intraocular pressure.

How significant is the patent expiration impact on BETAGAN?

Patent expiration has led to increased generic competition, reducing prices and revenue margins significantly.

Are there ongoing developments to extend BETAGAN’s lifecycle?

Yes, research is ongoing into combination therapies and sustained-release formulations, which could extend market relevance.

Could BETAGAN be replaced by other eye droppers?

Yes. Prostaglandin analogs and other newer classes are increasingly replacing beta-blockers due to improved efficacy and fewer side effects.

What strategic moves can pharma firms consider for BETAGAN?

Investing in reformulations, developing combination drugs, and expanding into emerging markets can support revenue stability.

---

References

1. MarketsandMarkets. (2023). Glaucoma therapeutics Market report.
2. FDA. (2003). Approval documents for BETAGAN.
3. European Medicines Agency (EMA). (2019). Product approval details.
4. U.S. Patent and Trademark Office. (2020). Patent expiry notices.
5. Scrip Pharmaceutical Intelligence. (2022). Industry trend reports.

[1] MarketsandMarkets. (2023). Glaucoma therapeutics Market analysis.